BOSTON, Jan. 19 /PRNewswire/ -- The North American Thrombosis Forum (NATF), in coordination with Eisai Inc., announced today that three hospitals have been selected as recipients of the 2009 DVTeamCare Hospital Award. This new award was established by Eisai to recognize hospitals that have made a significant commitment to preventing deep vein thrombosis (DVT) and its potentially fatal complications, including pulmonary embolism (PE).
Throughout the year, NATF and Eisai invited healthcare professionals from across the country to nominate their hospital for the first annual DVTeamCare Hospital Award and share their protocols and implementation strategies for preventing DVT. The award is an extension of NATF's goal of enhancing thrombosis education, prevention, diagnosis, and treatment to improve patient outcomes and Eisai's human health care (hhc) mission, which is to give first thought to patients and their families, and to increasing the benefits that health care provides.
The Johns Hopkins Hospital (Maryland) and the University of California, San Diego Medical Center tied as award recipients among hospitals with more than 200 beds. Washington DC Veterans Affairs Hospital is the award recipient among hospitals with less than 200 beds.
"We reviewed a series of submissions focused on VTE prevention," said John Fanikos, RPh, MBA, Treasurer of NATF and Assistant Director of Pharmacy at the Brigham and Women's Hospital. "The successful common denominator was multiple disciplines within a hospital, rolling up their sleeves, working together, and either using the tools available, or improving those tools, or creating new ones to improve VTE prophylaxis. The initiatives, the innovation, and the efforts were impressive."
In addition, awardees will also be recognized among their peers and presented with a commemorative plaque during the NATF Annual Thrombosis Prevention Forum in Boston, Massachusetts on April 10, 2010. After this presentation, the winning protocols and implementation plans will be made available at www.DVTeamCareAward.com to help other hospitals enhance their efforts to prevent DVT.
Twenty-two hospitals submitted nominations, which were evaluated by an independent panel of three judges selected by NATF. All judges are nationally and internationally recognized in the areas of thrombosis, hemostasis, and venous thromboembolism (VTE). The judges scored the submissions based on four criteria developed by NATF: intelligence/design of the protocol; implementation; results; and clarity/preparation of the nomination.
About Eisai Inc.
Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. Headquartered in Woodcliff Lake, New Jersey, the company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
About the North American Thrombosis Forum
NATF is a nonprofit organization that focuses on unmet needs and issues related to thrombosis and cardiovascular diseases such as deep vein thrombosis, pulmonary embolism, myocardial infarction, peripheral arterial occlusive disease, and stroke. The five areas of major focus are: 1) basic translational research, 2) clinical research, especially diagnosis and therapy, 3) prevention and education, 4) public policy, and 5) advocacy. NATF's legacy will be to improve patient care, outcomes, and public health by supporting thrombosis-related programs, such as novel research projects, innovative educational programs, public policy initiatives, regulatory issues and advocacy, and to broaden training opportunities for physicians, scientists, and other health professionals. For more information about NATF, please visit www.natfonline.org.
*NATF has been engaged to independently develop the criteria for and judge the Award and does not endorse or promote any product or service offered by Eisai Inc. or any Award nominee or recipient.
SOURCE Eisai Inc.
Advertisement
Throughout the year, NATF and Eisai invited healthcare professionals from across the country to nominate their hospital for the first annual DVTeamCare Hospital Award and share their protocols and implementation strategies for preventing DVT. The award is an extension of NATF's goal of enhancing thrombosis education, prevention, diagnosis, and treatment to improve patient outcomes and Eisai's human health care (hhc) mission, which is to give first thought to patients and their families, and to increasing the benefits that health care provides.
Advertisement
The Johns Hopkins Hospital (Maryland) and the University of California, San Diego Medical Center tied as award recipients among hospitals with more than 200 beds. Washington DC Veterans Affairs Hospital is the award recipient among hospitals with less than 200 beds.
"We reviewed a series of submissions focused on VTE prevention," said John Fanikos, RPh, MBA, Treasurer of NATF and Assistant Director of Pharmacy at the Brigham and Women's Hospital. "The successful common denominator was multiple disciplines within a hospital, rolling up their sleeves, working together, and either using the tools available, or improving those tools, or creating new ones to improve VTE prophylaxis. The initiatives, the innovation, and the efforts were impressive."
- The Johns Hopkins Hospital developed a mandatory computer-based decision support system to facilitate specialty-specific risk factor assessment and the application of risk-appropriate Venous Thromboembolism (VTE) prophylaxis.
- The University of California, San Diego Medical Center designed, piloted, and implemented a VTE prevention protocol across all medical and surgical services to achieve sustained high rates of VTE prophylaxis.
- The Washington DC Veterans Affairs Medical Center designed a 7-step process that walks providers through an evidence-based medicine risk factor assessment to determine appropriate thromboprophylactic therapy.
In addition, awardees will also be recognized among their peers and presented with a commemorative plaque during the NATF Annual Thrombosis Prevention Forum in Boston, Massachusetts on April 10, 2010. After this presentation, the winning protocols and implementation plans will be made available at www.DVTeamCareAward.com to help other hospitals enhance their efforts to prevent DVT.
Twenty-two hospitals submitted nominations, which were evaluated by an independent panel of three judges selected by NATF. All judges are nationally and internationally recognized in the areas of thrombosis, hemostasis, and venous thromboembolism (VTE). The judges scored the submissions based on four criteria developed by NATF: intelligence/design of the protocol; implementation; results; and clarity/preparation of the nomination.
About Eisai Inc.
Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. Headquartered in Woodcliff Lake, New Jersey, the company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
About the North American Thrombosis Forum
NATF is a nonprofit organization that focuses on unmet needs and issues related to thrombosis and cardiovascular diseases such as deep vein thrombosis, pulmonary embolism, myocardial infarction, peripheral arterial occlusive disease, and stroke. The five areas of major focus are: 1) basic translational research, 2) clinical research, especially diagnosis and therapy, 3) prevention and education, 4) public policy, and 5) advocacy. NATF's legacy will be to improve patient care, outcomes, and public health by supporting thrombosis-related programs, such as novel research projects, innovative educational programs, public policy initiatives, regulatory issues and advocacy, and to broaden training opportunities for physicians, scientists, and other health professionals. For more information about NATF, please visit www.natfonline.org.
*NATF has been engaged to independently develop the criteria for and judge the Award and does not endorse or promote any product or service offered by Eisai Inc. or any Award nominee or recipient.
SOURCE Eisai Inc.
